Liver Meeting 2025 Resource Hub –
Welcome to our resource hub for The Liver Meeting 2025! This is a one-stop-shop for all your The Liver Meeting 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Table of Contents []
Useful Conference Links
Day-of Conference Reports
Top Highlights
- President’s Welcome blends activism, public policy, and scientific advancement in hepatology
- Science at a crossroads: Dr. Francis Collins calls for rebuilding trust
- From clinic to Congress: Sen. Bill Cassidy’s mission to eradicate Hepatitis C
- Expanding roles of resmetirom: Dr. Naim Alkhouri on moving beyond at-risk MASH to cirrhosis, cardiovascular health, and high alcohol use
- GLP-1 RAs for steatotic liver disease: Semaglutide, tirzepatide, survodutide, and retatrutide, along with Madrigal’s Rezdiffra
- Efruxifermin demonstrates improvements to multiple non-invasive tests indicative of fibrosis regression in patients with compensated cirrhosis
- Real-world study shows that GLP-1 RAs improve liver-related outcomes more than bariatric surgery in people with T2D and obesity
- Phase 2b trial of AstraZeneca’s dual GLP-1/glucagon RA cotadutide demonstrates MASH resolution, weight loss, and A1c improvement
- Post hoc analysis of the ESSENCE trial: Liver-related health benefits of semaglutide beyond weight loss
- M-ACCEL trial results: HU6, an oral controlled metabolic accelerator, reduces liver fat and improves adiposity markers in adults with MASH
- Hans Popper State of the Art Lecture: Hacking the hepatic lipid code – mechanisms and therapeutic opportunities in steatotic liver disease
- MASLD Debrief: A continued need for screening, referral, and therapeutics for the future
- Post hoc analysis of MAESTRO-NAFLD-1: Resmetirom treatment for two years led to significant improvement in patients with compensated MASH cirrhosis
- Mazdutide, a once-weekly dual GLP-1/glucagon RA, demonstrates remarkable efficacy for the resolution of steatosis in over 60% of participants